Altre lingue aTyr Pharma, Inc. Deutsche Boerse AG

Azioni

471A

US0021202025

Mercato chiuso - Deutsche Boerse AG Altri mercati azionari 09:06:19 07/06/2024			Variaz. 5gg	Var. 1 gen.
1,67 ^EUR	+1,83%		+5,03%	+29,46%

05/06	ATyr Pharma, Inc. cambierà il suo ticker in ATYR. da LIFE	CI
14/05	ATyr Pharma, Inc. annuncia la seconda revisione DSMB positiva per Efzofitimod nello studio di Fase 3 EFZO-FIT? nella sarcoidosi polmonare	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

ATyr Pharma, Inc. will Change its Ticker to ATYR. from LIFE	05/06
ATyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”	03/06
ATyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	24/05
ATyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference	15/05
ATyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis	14/05
ATyr Pharma, Inc. Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT? Study in Pulmonary Sarcoidosis	14/05
ATyr Pharma to Present at Upcoming Investor Conferences	06/05
Atyr Pharma: Q1 Earnings Snapshot	02/05
ATyr Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05
Earnings Flash (LIFE) ATYR PHARMA Reports Q1 Revenue $235,000	02/05
ATyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update	02/05
ATyr Pharma to Participate in April Investor Conferences	01/04
ATyr Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/03
Atyr Pharma: Q4 Earnings Snapshot	14/03
ATyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update	14/03
ATyr Pharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	14/03
ATyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results	28/02
ATyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants	21/02
ATyr Pharma, Inc. Announces Plans to Initiate an Individual Patient Expanded Access Program for Its Lead Therapeutic Candidate, Efzofitimod, for Patients with Pulmonary Sarcoidosis	21/02
ATyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity	29/01

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue aTyr Pharma, Inc. Deutsche Boerse AG

Azioni

471A

US0021202025

Altre lingue

Filtri